IX: Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis

Cranney, Ann; Guyatt, Gordon; Griffith, Lauren; Wells, George; Tugwell, Peter; Rosen, Clifford J.

doi:10.1210/er.2001-9002

Cited by 525 publications

(246 citation statements)

References 30 publications

Supporting

Mentioning

229

Contrasting

Unclassified

Order By: Relevance

“…The efficacy of a bisphosphonate (an anti-resorptive drug), risedronate, for postmenopausal osteoporosis has been established: risedronate reduces the incidence of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis [3]. Recently, however, it has been reported that suppressed bone turnover by long-term treatment with high-dose risedronate increased microdamage accumulation in the dog rib [11], suggesting long-term and/or high-dose risedronate treatment may deteriorate bone quality through microdamage accumulation.…”

Section: Introductionmentioning

confidence: 99%

Effect of Pre- and Post-Surgery Treatment with Risedronate on Trabecular Bone Loss in Ovariectomized Rats

et al. 2006

View full text Add to dashboard Cite

The purposes of the present study were to differentiate the effects of pre-surgery treatment with risedronate and post-surgery treatment with a reduced dosing frequency of risedronate on trabecular bone loss in ovariectomized rats and to determine whether postsurgery treatment with a reduced dosing frequency of risedronate would have a beneficial effect on trabecular bone loss after pre-surgery treatment Materials and Methods Treatment of animalsOne hundred female Sprague-Dawley rats, 3 months of age, were purchased from Charles River Lab (Wilmington, MA, USA). The animals were housed under local vivarium conditions (temperature 23.8°C and 12 h on/off light cycle), and were fed a pelleted standard chow diet (Purina Mills Prolab RMH 2500 Rodent diet #5P14, ON, USA), with free access to water. The rats were used after allowing one-month adaptation to the new environment.The present study included short-term (6 weeks) and long-term (10 weeks) experiments. The short-term experiment was performed on fifty rats. Rats were randomized by the stratified weight method into five groups of 10 rats each (Fig. 1). In detail, 40 rats were divided into two groups with 20 rats in each group. Twenty rats were treated with vehicle for 4 weeks before ovariectomy (OVX) (Vehicle-OVX), and another 20 rats were treated with risedronate for 4 weeks before OVX (Risedronate-OVX). Then, 20 rats in each group were subdivided into two groups of 10 rats each. The 20 rats treated with vehicle before OVX were treated with vehicle (10 rats) or risedronate (10 rats) for 2 weeks following OVX (the Vehicle-OVX-Vehicle [OVX control] and Vehicle-OVX-Risedronate [post-OVX treatment with risedronate] groups, respectively), and the 20 rats treated with risedronate before OVX were treated with vehicle (10 rats) or risedronate (10 rats) for 2 weeks following OVX (the Risedronate-OVX-Vehicle [pre-OVX treatment with risedronate] and Risedronate-OVX-Risedronate [continuous treatment with risedronate] groups, respectively). The remaining 10 rats were treated with vehicle for 6 weeks, with a sham operation performed 4 weeks after the start of the experiment (the Vehicle-Sham-Vehicle [Sham control] group). During the 4 weeks prior to surgery, risedronate (Aventis Pharma, Tokyo, Japan) was dissolved in 0.1

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of Pre- and Post-Surgery Treatment with Risedronate on Trabecular Bone Loss in Ovariectomized Rats

et al. 2006

View full text Add to dashboard Cite

show abstract

“…2,3 In turn, their effects on the reduction of non-vertebral fractures, including hip, is quite variable. [4][5][6] Until recently, the evaluation of drug effects on trabecular and cortical bone microarchitecture was made by histomorphometric analysis and micro-computed tomography of bone biopsy specimen. 7 Although dynamic histomophometric analysis of iliac crest bone biopsies is still necessary to assess bone mineral apposition rate and cellular activities, 8 the development of high-resolution peripheral quantitative computed tomography (HR-pQCT) allows non-invasive assessment of volumetric density and some parameters of bone microstructure at peripheral sites in vivo.…”

Section: Introductionmentioning

confidence: 99%

Osteoporosis drug effects on cortical and trabecular bone microstructure: a review of HR-pQCT analyses

Lespessailles¹,

Hambli

Ferrari

2016

BoneKEy Reports

View full text Add to dashboard Cite

With the development of new non-invasive analytical techniques and particularly the advent of high-resolution peripheral quantitative computed tomography (HRpQCT) it is possible to assess cortical and trabecular bone changes under the effects of ageing, diseases and treatments. In the present study, we reviewed the treatment-related effects on bone parameters assessed by HRpQCT imaging. We identified 12 full-length articles published in peer-reviewed journals describing treatment-induced changes assessed by HRpQCT. The design of these studies varied a lot in terms of duration and methodology: some of them were open-labelled, others were double-blind, placebo-controlled or doubleblind, double-dummy, active controlled. In addition, the sample size in these studies ranged from 11 to 324 patients. Motion artifacts occurring during data acquisition were sometimes a real challenge particularly at the radius leading sometimes to exclude the analysis at the radius due to the uninterpretability of microstructural parameters. Responses to therapies were treatment-specific and divergent effects in cortical and trabecular bone with antiresorptive or anabolic agents were observed. Standardization of bone microarchitecture parameters (including porosity) and bone strength estimates by finite element analysis (FEA) are mandatory. The additional value of microarchitecture and FEA estimates changes with therapies in terms of improvement in fracture outcomes which have to be adequately assessed in clinical trials with fracture end point. Data from these reviewed studies advance our understanding of the microstructural consequences of osteoporosis and highlight potential differences in bone quality outcomes within therapies.

show abstract

“…However, BMD has demonstrated limitations for predicting bone fracture and understanding the roles of estrogen in bone quality, formation and resorption. [3][4][5] In particular, BMD is unable to assess changes in Type I collagen structure that are keys to understanding bone toughness. The structural changes that occur in Type I collagen matrix under conditions of estrogen depletion and drug treatment remain largely unknown.…”

Section: Introductionmentioning

confidence: 99%

Alteration of Type I collagen microstructure induced by estrogen depletion can be prevented with drug treatment

Cauble¹,

Rothman²,

Welch³

et al. 2015

BoneKEy Reports

View full text Add to dashboard Cite

Two independent biological replicates of estrogen depletion were employed with differing drug treatment conditions. Data Set I consisted of 9-month-old New Zealand white female rabbits treated as follows: sham-operated (n ¼ 11), ovariectomized (OVX; n ¼ 12), OVX þ 200 mg kg À 1 alendronate (ALN), 3 Â a week for 27 weeks (n ¼ 12) and OVX þ 10 mg kg À 1 Cathepsin-K inhibitor (CatKI) daily for 27 weeks. Data Set II consisted of 6-month-old New Zealand white female rabbits that were sham-operated (n ¼ 12), OVX (n ¼ 12) or OVX þ 0.05 mg kg À 1 17b-estradiol (ERT) 3 Â a week for 13 weeks (n ¼ 12). Samples from the cortical femur were polished and demineralized to make them suitable for atomic force microscopy (AFM) imaging. Type I collagen fibrils present in bundles or sheets, running parallel to each other, were combined into a class termed Parallel. Fibrils present outside of such structures, typically in images with an angular range of non-parallel fibrils, were combined into a class termed Oblique. The percentage of fibrils coded as Parallel for Sham animals in Data Sets I and II was 52% and 53%, respectively. The percentage of fibrils coded as Parallel for OVX animals in Data Sets I and II was 35% in both cases. ALN and ERT drug treatments reduced the change from 18 to 12%, whereas CatKI treatment reduced the change to 5%.

show abstract

IX: Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis

Cited by 525 publications

References 30 publications

Effect of Pre- and Post-Surgery Treatment with Risedronate on Trabecular Bone Loss in Ovariectomized Rats

Effect of Pre- and Post-Surgery Treatment with Risedronate on Trabecular Bone Loss in Ovariectomized Rats

Osteoporosis drug effects on cortical and trabecular bone microstructure: a review of HR-pQCT analyses

Alteration of Type I collagen microstructure induced by estrogen depletion can be prevented with drug treatment

Contact Info

Product

Resources

About